Introduction {#s1}
============

Retinopathy is a common complication of prematurity, and routine screening examinations are essential for timely diagnosis of retinopathy of prematurity (ROP). It is essential to have timely diagnosis and treatment of ROP, to prevent permanent blindness in premature neonates; however, it is essential that we have both safe and effective mydriatic regimens.

Mydriatic medicines play an essential diagnostic role; however, there are clinically significant risks associated with using mydriatics. There are concerns about the limited evidence that is used to support safe and effective mydriatic regimens, for retinopathy of prematurity eye examinations (ROPEE).

Various combinations of phenylephrine, cyclopentolate and tropicamide are commonly used to prepare the neonatal for the ROPEE. However, the lowest effective dose has not been substantiated with a large data set nor has the evaluation of microdrop (md) to standard drop (d) administration. Pupil dilation results from standard and microdrop size was included in the analysis, and for the purposes of this paper, a standard drop size is considered to be approximately 26 µL, and a microdrop size is approximately 7 µL.[@R1]

The main safety concerns surrounding mydriatic medicines are ones associated with systemic absorption following ocular administration. Following ocular delivery, it is estimated that approximately 80% of the eye drop volume enters the nasolacrimal duct, therefore gaining entry into the systemic circulation via the nasal mucosa.[@R2] Systemic absorption of mydriatics have been associated with clinically significant, and sometimes life-threatening cardiovascular, respiratory, central nervous system (CNS) and gastrointestinal adverse effects. Examples of some adverse effects include: hypertension, hypotension, tachycardia, bradycardia, apnoea, cardiopulmonary arrest, seizures, necrotising enterocolitis (NEC), sepsis and death.

Management of these side effects are challenging and premature infants have less ability to cope with the associated problems. Management of side effects in premature infants born in the developing world is of great concern as they are likely to have reduced access to care and management of the associated complications.

International guidelines play an essential role in directing best practice worldwide. The two readily available international guidelines for ROPEE are the UK Guideline for the Screening and Treatment of Retinopathy of Prematurity, 2008 and the American Policy Statement on Screening Examination of Premature Infants for Retinopathy of Prematurity, 2013.[@R3]

The UK guideline recommends phenylephrine 2.5% and cyclopentolate 0.5%, 2--3 d; however, a lower dose regimen is favourable but not recommended because a proprietary product is not available. In comparison, the American policy statement does not provide any recommendations for suitable mydriatic agents and regimens.

This robust review of the literature evaluates the evidence for both the safety and efficacy aspects of mydriatic regimens used during ROP screening.

Methods {#s2}
=======

One review author (LK) searched the published literature looking for reports on the safety and/or efficacy during 2017 and 2018.

Databases used {#s2-1}
--------------

The following databases were used: EMBASE, MEDLINE via Ovid, PubMed, Web of Science, Cochrane Library and Cochrane Neonatal Review Group and Google Scholar. Date restricted 1970 onwards. Refer to [online appendix 1](#SP1){ref-type="supplementary-material"} for Medline search strategy.
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Other {#s2-2}
-----

Additional records were identified through reference review of sourced literature.

Keywords used {#s2-3}
-------------

The following keywords were used 'phenylephrine', 'cyclopentolate', 'tropicamide', 'mydriasis', 'pupil dilation', 'adverse effects', 'administration and dosage', 'eye drops', 'ophthalmic solutions', 'pupil'. Subject heading: 'infant, newborn, premature', 'efficacy', 'safety'. It was considered that the following were synonymous with mydriasis: pupil dilation and pupil dilatation.

Inclusion criteria {#s2-4}
------------------

Participants are premature infants, interventions are mydriatic medicine administration, comparisons of efficacy are between different mydriatic regimens, comparisons of safety are between baseline and any adverse effect, outcomes for efficacy are either pupil dilation measurements or successful eye examination, outcomes for safety are any adverse effects, study design includes all study designs including pilot and case reports. Full text is available in English.

Exclusion criteria {#s2-5}
------------------

Full text not available in English, published after 1970, commentary, letters to the editor, publications on; pain associated with ROP procedure, physiology and ophthalmic formulation; paediatric participants.

Study selection {#s2-6}
---------------

Screening and eligibility assessment was performed independently in an unblinded standardised manner by one reviewer (LK). No data was meta-analysed due to the high variability of the mydriatic regimens.

Data collection process {#s2-7}
-----------------------

Included studies were entered into EndNote, and the 'remove duplicates' function was utilised. Online trial registration for all intervention studies was accessed (when available) and study design was compared with publication results.

Studies that reported pupil dilation data were entered into Microsoft Excel and a forest plot was created using GraphPad PRISM (V.7.04). Some of the pupil dilation data needed to be converted into measurement (mm) and rounded to the nearest decimal point. Studies that reported blood pressure and heart rate data were collated in a Microsoft Word table. Some of the blood pressure results were converted into percentage increase or decrease.

Data items {#s2-8}
----------

Information was extracted from each included trial on: (1) characteristics of trial participants (including gestational age, birth weight) and the trial's inclusion and exclusion criteria; (2) type of intervention (mydriatic(s) used, concentration, number of administrations, timing of dosing; (3) type of outcome measure (including pupil dilation measurement, effects on cardiovascular, gastrointestinal, respiratory, dermal and CNS and other).

Risk of bias {#s2-9}
------------

Cochrane methodology was used to assess risk of bias for RCTs and results analysed using Review Manager (V.5.3). Risk of bias in non-randomised studies - of interventions (ROBINS-I) tool was used to assess risk of bias for non-randomised intervention trials, and observational studies were assessed for bias using the National Heart, Lung and Blood Institute (NHLBI) checklist.[@R5]

Summary measures {#s2-10}
----------------

Where available, the difference in means (±SD) data was obtained from the pupil dilation (efficacy) and safety measurements (eg, blood pressure, heart rate).

Results {#s3}
=======

One hundred and eighty six studies were identified, and of these, 47 publications were included in the systematic review ([figure 1](#F1){ref-type="fig"}). Efficacy and safety data were extracted from the publications, and safety data were further subcategorised into themes of cardiovascular, gastrointestinal, respiratory, CNS, dermal and other effects ([table 1](#T1){ref-type="table"}). All trials occurred at a single centre.

![Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram.](bmjpo-2019-000448f01){#F1}

###### 

Summary of characteristics and demographics for publications (excluding case reports)

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Paper                            Design                         Regimen                        Mean (SD) GA          Mean (SD) BW (g)   Sample Size   Efficacy   Safety
  -------------------------------- ------------------------------ ------------------------------ --------------------- ------------------ ------------- ---------- -------------
  Alshafei (2017)[@R6]             Observational prospective      P 2.5%, T 5% (3 d)             24--31                --                 42                       R

  Bolt (1992)[@R7]\                Quasi-RCT\                     P 2.5% (1d), T 0.5% (2 d)      32.3 (±3.3) weeks     1544 (±761)        20            ✓          C
                                                                                                                                                                   

  C 0.5% (1d), T 0.5% (2 d)        34.6 (±3.6) weeks              1831 (±645)                    19                    ✓                  C                        

  Bonthala (2000)[@R8]             Non-randomised intervention    P 1%, C 0.2% (2 d)             29--33                1340 (±82)         11                       C

  Caputo (1982)[@R9]\              Quasi-RCT\                     P 2.5%, C 0.5%, T 0.5% (1 d)   26--42 weeks          880--3440          10            ✓          
                                                                                                                                                                   

  P 2.5%, C 0.5%, T 0.5% (2 d)     26--42 weeks                   880--3440                      10                    ✓                                           

  Chew (2005)[@R20]\               RCT\                           P 2.5%, C 1% (3 d)             29.92 (±2.66) weeks   --                 13            ✓          G
   \                                \                                                                                                                              
                                                                                                                                                                   

  P 2.5%, T 1% (3 d)               29.23 (±1.59) weeks            --                             13                    ✓                  G                        

  P 1%, C 0.2% (3 d)               29.15 (±2.54) weeks            --                             13                    ✓                  G                        

  Elibol (1997)[@R17]\             Quasi-RCT\                     C 1% (2 d or 2 microd)         39.68 (±34.33) days    --                16            ✓          C, D
   \                                \                                                                                                                              
                                                                                                                                                                   

  P 10% (2 d or 2 microd)          22.83 (±21.39) days            --                             18                    ✓                  C, D                     

  T 0.5% (2 d or 2 microd)         28.78 (±26.89) days            --                             19                    ✓                  C, D                     

  Isenberg (1985)[@R15]\           RCT\                           C 0.25% (2 d)                  31 (±2) weeks         1233 (±390)        6                        G
   \                                \                                                                                                                              
                                                                                                                                                                   

  C 0.5% (2 d)                     31 (±2) weeks                  1233 (±390)                    8                                        G                        

  Saline 0.9%                      31 (±2) weeks                  1233 (±390)                    6                                                                 

  Isenberg (1984 March)[@R18]\     Non-randomised intervention\   C 0.5% (2 d)                   --                    1198 (±220)        10            ✓          C
   \                                \                                                                                                                              
                                                                                                                                                                   

  C 0.5%, T 0.5% (2 d)             --                             1227 (±220)                    10                    ✓                  C                        

  P 1%, C 0.2% (2 d)               --                             1273 (±251)                    10                    ✓                  C                        

  Isenberg (1984 July)[@R40]\      Non-randomised intervention\   C 0.5% (2 d)                   --                    1178 (±208)        12            ✓          C
   \                                \                                                                                                                              
   \                                \                                                                                                                              
                                                                                                                                                                   

  P 1%, C 0.2% (2 d)               --                             1282 (±207)                    12                    ✓                  C                        

  P 2.5%, T 0.5% (2 d)             --                             1135 (±282)                    12                    ✓                  C                        

  Saline                           --                             --                             6                     ✓                  C                        

  Jiang (2016)[@R10]               Observational retrospective    P 0.5%, T 0.5% (3 d)           --                    --                 1254                     C, R

  Khoo (2000)[@R16]\               RCT crossover\                 P 1%, C 0.2% (3 d)             26.2 weeks\           --                 28            ✓          C
                                                                                                 (test 1)\                                                         
                                                                                                 35.8 weeks\                                                       
                                                                                                 (test 2)                                                          

  P 2.5%, T 0.5% (3 d)             26.2 weeks\                    --                             28                    ✓                  C                        
                                   (test 1)\                                                                                                                       
                                   36.1 weeks\                                                                                                                     
                                   (test 2)                                                                                                                        

  Laws (1996)[@R11]                Observational prospective      P 2 5% (2d), C 0.5% (4 d)      27.1 (±2.4)           1003 (±332)        56                       C

  Lees (1981)[@R12]                Observational prospective      P 2.5%, T 0.5% (1 d)           31 (±3.12)            1450 (±464)        7                        C

  Luo (2014)[@R21]\                RCT crossover\                 P 0.5%, T 0.5% (3 d)           26--37 weeks          --                 88            ✓          
                                                                                                                                                                   

  P 0.25%, T 0.25% (3 d)           26--37 weeks                   --                             88                    ✓                                           

  Lux (2016)[@R27]\                RCT\                           T 0.5% (3 d)                   --                    --                 30            ✓          
                                                                                                                                                                   

  P 5% (1 d), T 0.5% (2 d)         --                             --                             30                    ✓                                           

  Merrit (1981)[@R45]\             RCT\                           P 2.5%, T 1% (3 d)             32 (±0.5)             1569 (±98.7)       52                       C
                                                                                                                                                                   

  P 2.5%, T 0.5%, C 0.5% (3 d)     30.2 (±0.4)                    1250.7 (±61.6)                 30                                       C                        

  Mirmanesh (1992)[@R22]           Non-randomised Intervention    P 2.5% (3 d)                   27 (±2)               840 (±200)         21                       R

  Mitchell (2016)[@R28]            RCT                            P 1%, C 0.2% (3 d)             28.5 (±2.8)           1148 (±523)        25                       G, R

  Mitchell (2011)[@R46]            Observational prospective      P 1%, C 0.2% (3 d)             28.24 (±2.62)         1161 (±352)        50                       R, C, G, N

  Neffendorf (2015)[@R43]          Observational retrospective    P 2.5%, C 0.5% (3 d)           29 (no SD)            1234 (no SD)       138           ✓          R, C, other

  Ogut (1996)[@R26]\               Non-randomised intervention\   P 2.5%, C 0.5%, T 0.5% (1 d)   39.4 weeks            3150               10            ✓          
   \                                \                                                                                                                              
   \                                \                                                                                                                              
   \                                \                                                                                                                              
   \                                \                                                                                                                              
   \                                \                                                                                                                              
   \                                \                                                                                                                              
                                                                                                                                                                   

  P 2.5%, T 1% (1 d)               39.4 weeks                     3150                           10                    ✓                                           

  P 2.5%, C 1% (2 d)               39.4 weeks                     3150                           10                    ✓                                           

  C 1%, T 1% (1 d)                 39.4 weeks                     3150                           10                    ✓                                           

  P 2.5% (2 d)                     39.4 weeks                     3150                           10                    ✓                                           

  C 1% (2 d)                       39.4 weeks                     3150                           10                    ✓                                           

  T 1% (2 d)                       39.4 weeks                     3150                           10                    ✓                                           

  Saline 0.9%                      39.4 weeks                     3150                           10                    ✓                                           

  Phamonvaechavan (2012)[@R23]\    RCT crossover\                 P 2.5%, T 0.75% (2d)           30.5 weeks            1241.9             21            ✓          C
                                                                                                                                                                   

  P 2.5%, T 0.75% (2 d)            30.5 weeks                     1241.9                         21                    ✓                  C                        

  Punyawattanaporn (2009)[@R41]\   RCT\                           P 1%, C 0.2% (1 d)             30.49 (2.34)          1368 (438.99)      70            ✓          R
                                                                                                                                                                   

  P 1%, C 0.2% (3 d)               30.49 (2.34)                   1368 (438.99)                  70                    ✓                  R                        

  Rosales (1981)[@R24]             Observational prospective      P 2.5%, T 0.5% (3 d)           --                    --                 10                       C

  Rush (2004)[@R25]                Observational prospective      P 2.5%, T 0.5% (3 d)           --                    --                 30                       R, C

  Sindel (1986)[@R19]\             RCT\                           P 2.5%, T 1% (2 d)             28.0 (1.9) weeks      1022 (226)         10            ✓          C
   \                                \                                                                                                                              
                                                                                                                                                                   

  P 2.5%, T 0.5% (2 d)             28.3 (1.6) weeks               1115 (281)                     10                    ✓                  C                        

  P 1%, T 1% (2 d)                 29.0 (2.4) weeks               1110 (317)                     10                    ✓                  C                        

  Vicente (2012)[@R42]\            RCT\                           P 1%, C 0.2% (1 d)             28.7 (2.6) weeks      --                 5             ✓          
   \                                \                                                                                                                              
                                                                                                                                                                   

  P 1%, C 0.2% (2 d)               28.7 (2.6) weeks               --                             10                    ✓                                           

  P 1%, C 0.2% (3 d)               28.7 (2.6) weeks               --                             15                    ✓                                           

  Wheatcroft (1993)[@R1]\          Non-randomised intervention\   P 2.5%, C 0.5%, (2 d)          29.8 weeks            1238               26            ✓          
                                                                                                                                                                   

  P 2.5%, C 0.5%, (2 microd)       29.8 weeks                     1238                           26                    ✓                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Efficacy was identified if authorsmeasured pupil dilation or successful retinopathy of prematurity eye examinations. Safety was determined if physiological measurements were taken.

BW, birth weight;C, cardiovascular;C, cyclopentolate;D, dermal; G, gastrointestinal; GA, gestational age;P, phenylephrine;R, respiratory;RCT, randomised controlled trial;T, tropicamide;d, standard drop;microd, microdrop.

Risk of bias for all studies are summarised in [figure 2](#F2){ref-type="fig"} and in [tables 2 and 3](#T2 T3){ref-type="table"}.

![Cochrane tool risk of bias summary for randomised controlled trial (RCT) or quazi-RCT studies. Review authors\' judgements about each risk of bias item for each included study. Key: '--' indicates high risk of bias; '?' indicates unclear risk of bias; '+' indicates low risk of bias.](bmjpo-2019-000448f02){#F2}

###### 

ROBINS-I overall risk of judgement for non-randomised intervention studies

  Study                         Judgement                                                                                                                                                                                                                       Criterion
  ----------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bonthala (2000)[@R8]          The study has some important problems.                                                                                                                                                                                          The study is judged to be at serious risk of bias across the confounding and selection of participants domains, but not at critical risk of bias in any domain.
  Isenberg (1984 March)[@R18]   The study has some important problems.                                                                                                                                                                                          The study is judged to be at serious risk of bias in classification of intervention domain, but not at critical risk of bias in any domain.
  Isenberg (1984 July)[@R40]    The study provides sound evidence for a non-randomised study but cannot be considered comparable to a well-performed randomised trial.                                                                                          The study is judged to be at low or moderate risk of bias for all domains, except for bias due to missing data as there was insufficient information provided.
  Mirmanesh (1992)[@R22]        The study provides sound evidence for a non-randomised study but cannot be considered comparable to a well-performed randomised trial.                                                                                          The study is judged to be at low or moderate risk of bias for most domains; however, there was insufficient information to determine bias in deviation from intervention, missing data and outcome measures.
  Ogut (1996)[@R26]             The study provides sound evidence for a non-randomised study but cannot be considered comparable to a well-performed randomised trial.                                                                                          The study is judged to be at low or moderate risk of bias for most domains; however, there was insufficient information to determine bias in selection of participants, deviation from intended intervention and missing data.
  Wheatcroft (1993)[@R1]        The study provides sound evidence for a non-randomised study but cannot be considered comparable to a well-performed randomised trial because there is a significant lack of information in the methods section of the paper.   The study is judged to be at low or moderate risk of bias for most domains; however, there was insufficient information to determine bias in selection of participants, deviation from intended intervention, missing data and the reported results.

###### 

National Heart Lung and Blood Institute overall risk of judgement for observational studies

  Study                     Judgement
  ------------------------- -----------
  Alshafei (2017)[@R6]      Fair
  Jiang (2016)[@R10]        Good
  Laws (1996)[@R11]         Fair
  Lees (1981)[@R12]         Fair
  Mitchell (2011)[@R46]     Good
  Neffendorf (2015)[@R43]   Good
  Rosales (1981)[@R24]      Poor
  Rush (2001)[@R25]         Fair

Efficacy {#s3-1}
--------

### Key findings {#s3-1-1}

1.  The majority of published data are from pilot studies that had a significant amount of unclear to high risk of bias; therefore, there is no strong evidence to support clinical practice ([figure 2](#F2){ref-type="fig"}).

2.  There is a wide range of mydriatic concentrations and frequency of administration in the published literature.

3.  Almost all mydriatic regimens included in this review demonstrated sufficient pupil dilation of above 5 mm ([figure 3](#F3){ref-type="fig"}).

4.  The lowest effective regimen appears to be phenylephrine 1% and cyclopentolate 0.2%, 1 d of each.

5.  Microdrop administration of mydriatic medicines are likely to sufficiently dilate the pupil.

![Pupil dilation results (mean and 95% CI) for treatment arms in RCTs, including quasi-RCT and cross-over RCT. The dotted line is the estimated pupil dilation (5 mm) that is required for an ophthalmologist to perform a successful retinopathy of prematurity eye examinations. C, cyclopentolate; d, drop; micro, microdrop; P, phenylephrine; RCT, randomised controlled trial; T, tropicamide.](bmjpo-2019-000448f03){#F3}

Fifteen studies measured pupil dilation to ascertain efficacy and one publication (Neffendorf 2014) measured efficacy as a successful ROPEE. Participants were all premature infants and the number of participants in the studies ranged from 5 to 138. Study design was either RCT, quasi-RCT, cross-over controlled RCT, or an audit; however, the majority of the studies were quasi-RCTs and the majority had small sample sizes. Within these studies, the mydriatic regimens, method of measuring pupil diameter, physiological measures (eg, blood pressure, feed intolerance) all varied significantly. Because of this diverse range of mydriatic regimens and study methodology, comparisons across papers posed some difficulty and therefore highlights the need for robust evidence to guide clinical practice.

Additionally, within these 16 studies, there were 33 different regimens using various combinations of phenylephrine, cyclopentolate and tropicamide ([table 1](#T1){ref-type="table"}).

Only three regimens did not achieve sufficient pupil dilation above 5 mm: monotherapy with phenylephrine 10% (2 d and 2 microd)[@R6] and tropicamide 0.5% (3 d).[@R7] However, all other regimens, irrespective of concentration and frequency, did provide sufficient dilation ([figure 3](#F3){ref-type="fig"}). Data from Isenberg (1984 March and July) is not included in [figure 3](#F3){ref-type="fig"}, because net pupil dilation results were not available.[@R8] Data from Wheatcroft (1993) was also unable to be used in [figure 3](#F3){ref-type="fig"} because SD results were not available.[@R1]

Overall, the efficacy studies had a significant amount of unclear bias. Of concern, the majority of these studies had unclear randomisation generation, allocation concealment, blinding of personnel and participants ([figure 2](#F2){ref-type="fig"}).

Safety {#s3-2}
------

### Key findings {#s3-2-1}

1.  The majority of safety specific data is from low level study design studies; therefore, there is limited evidence to support clinical practice ([figure 2](#F2){ref-type="fig"} and [tables 2 and 3](#T2 T3){ref-type="table"}).

2.  There is a diverse range of safety aspects evaluating mydriatic safety.

3.  Multiple measures were used to evaluate mydriatic safety.

Twenty-two studies investigated safety aspects of the mydriatic regimens ([table 1](#T1){ref-type="table"}). Within case reports, there were 30 adverse events post-mydriatic administration.

Participants in the safety studies and case reports were all premature infants. The safety study design was either RCT, non-randomised intervention, observational, retrospective audits or case reports. The majority of the studies were non-randmoised intervention studies, and the sample size between the safety studies ranged from 7 to 1183. Within these studies, the mydriatic regimens, physiological measures (eg, blood pressure, feed intolerance) all varied significantly. This was similar for the case report analysis. Comparisons across papers created difficulty because of the variation in study design, low level of study design and the wide range of mydriatic regimens.

Cardiovascular {#s3-3}
--------------

### Key findings {#s3-3-1}

1.  Systemic absorption of phenylephrine causes vasoconstriction, resulting in increased blood pressure and tachycardia,[@R10] whereas anticholinergics can cause transient bradycardia, followed by tachycardia, palpitation and arrhythmias.[@R13] Both increases and decreases in blood pressure and heart rate were reported in the literature.

2.  There is a wide range of both mydriatic regimens and blood pressure measures, therefore, making the interpretation of cardiovascular effects challenging.

3.  Clinical significance is difficult to determine due to inability to adjust for confounders and gestational age of infants.

4.  No statistically significant changes in blood pressure and heart rate were seen with microdrop administration.

5.  Case reports highlight serious adverse effects such as cardiopulmonary arrest and pulseless.

A number of authors have investigated blood pressure and heart rate adverse effects associated with mydriatics ([table 4](#T4){ref-type="table"}). All results in [table 4](#T4){ref-type="table"} are after mydriatic administration, but before ROPEE, which is important as ROPEE is a confounder due to the oculocardio reflex-mediated reduction in heart rate, of approximately 10%, following ROPEE.[@R14]

###### 

Blood pressure and heart rate adverse effects for studies with p values, percentage change from baseline

  ---------------------------------------------------------------------------------------------------------------------------------------
  Paper                          Regimen                     mBP (mm Hg) ±SD   mDBP (mm Hg) ±SD   mSBP (mm Hg) ±SD   mHR (beats/min)±SD
  ------------------------------ --------------------------- ----------------- ------------------ ------------------ --------------------
  Bonthala (2000)[@R8]           P 1%, C 0.2% (2 d)          ↓ 11.5±5.8%\*     --                 --                 ↑ 0.6±1.2%\*

  Bolt (1992)[@R7]\              P 2.5% (1d), T 0.5% (2 d)   ↓ 4%              --                 --                 ↓ 1%
                                                                                                                     

  C 0.5% (1d), T 0.5% (2 d)      ↑ 5.1%\*                    --                --                 ↑ 3.7%†            

  Elibol (1997)[@R17]\           C 1% (2 d)                  ↑ 16.2%±2.2%\*†   --                 --                 ‡
   \                                                                                                                 
   \                                                                                                                 
   \                                                                                                                 
   \                                                                                                                 
                                                                                                                     

  C 1% (2 microd)                ↓ 1%±2.3%\*†                --                --                 ‡                  

  P 10% (2 d)                    ↑ 8%±0.2%\*†                --                --                 ‡                  

  P 10% (2 microd)               0±1.9%\*                    --                --                 ‡                  

  T 0.5% (2 d)                   ↑ 17.5%±0.2%\*†             --                --                 ‡                  

  T 0.5% (2 microd)              ↓ 1.4 ± 0.3%\*              --                --                 ‡                  

  Isenberg (1984 March)[@R40]\   C 0.5% (2 d)                ↓10%±12%†         --                 --                 ↑ 7.5%±18%
   \                                                                                                                 
                                                                                                                     

  C 0.5%, T 0.5% (2 d)           ↓ 10%±12%†                  --                --                 ↑ 7.5%±18%         

  P 1%, C 0.2% (2 d)             ↓ 5.8%±14%†                 --                --                 ↓ 1.7%±11%         

  Isenberg (1984 July)[@R18]\    C 0.5%                      ↓ 13.2%                                                 ↓ 3.3%
   \                                                                                                                 
                                                                                                                     

  P 1%, C 0.2%                   ↓ 3.8%                                                           ↓ 4.3%             

  P 2.5%, T 0.5%                 ↑ 19.6%                                                          ↓ 5.2%             

  Jiang (2016)[@R10]             P 0.5%, T 0.5% (3 d)        --                ↑ 8.5\*†           ↑ 5.4%\*§          --

  Khoo (2000)[@R16]\             P 1%, C 0.2% (3 d)          ↑ 3.7%            −1%                ↑ 0.8%             ↓ 4.5%
                                                                                                                     

  P 2.5%, T 0.5% (3 d)           ↓ 0.4%                      ↓ 0.3%            ↓ 1.2%             ↓ 6.6%             

  Laws (1996)[@R11]              P 2.5% (2d), C 0.5% (4 d)   --                ↑ 4.8%\*           ↑ 5%\*             ↓ 1.3%\*

  Lees (1981)[@R12]              P 2.5%, T 0.5% (1 d)        ↑ 19.4%†          ↑ 19.1%†           ↑ 17.1%†           0%

  Merritt (1981)[@R45]\          P 2.5%, T 1% (3 d)          --                --                 0%                 --
                                                                                                                     

  P 2.5%, T 0.5%,\               --                          --                0%                 --                 
  C 0.5% (3 d)                                                                                                       

  Phamonvaechavan (2012)[@R23]   P 2.5%, T 0.75% (2 d)       --                0%                 0%                 ↓ 3.2%

  Sindel (1986)[@R19]\           P 2.5%, T 1% (2 d)          ↓ 17.1%±10.4%†    --                 --                 --
   \                                                                                                                 
                                                                                                                     

  P 2.5%, T 0.5%,\               ↑ 22.8%±17.4%†              --                --                 ↑ 10.0%±10.6%†     
  C 0.5% (2 d)                                                                                                       

  P 1%, T 1% (2 d)               ↑ 7.7%±9.3%†                --                --                 --                 
  ---------------------------------------------------------------------------------------------------------------------------------------

\*Data approximated from graph or was converted to percentage.

†P\<0.05 to 0.01.

‡Data not presented.

§P=0.08.

C, cyclopentolate;P, phenylephrine;T, tropicamide;d, standard drop;mDBP, mean diastolic blood pressure;mHR, mean heart rate;mSDP, mean systolic blood pressure;microd, microdrop.

Evidence collected from a retrospective audit, with a sample size of 1254 premature infants, showed significant increases in blood pressure after administration of phenylephrine 0.5% and tropicamide 0.5%, 3 d (mean diastolic blood pressure 8.5% (p=0.04), mean systolic blood pressure 5.4% (p=0.078)).[@R10] This was compared with other cardiovascular related data sets which were from pilot studies, and within these eight different regimens, statistically significant increases in mean blood pressure were seen. The range of these increases in mean blood pressure from baseline ranged from 3.7% (no SD) to 22.8±17.4% ([table 4](#T4){ref-type="table"}).[@R6] Because multiple mydriatic regimens were used in these studies, no causative regimen was identified as having more of an effect on blood pressure.

A reduction in blood pressure was also identified in some studies. Four of these mydriatic regimens in pilot studies found statistically significant reductions in mean blood pressure from baseline, and these ranged from 1±2.3% to 17.1±10.4%.[@R17]

Clinical significance of all of the blood pressure results is difficult to determine without directly comparing the results to the individual gestational age of the infant and adjusting for confounders.

Statistically significant changes in heart rate only occurred when two anticholinergic medicines were used. An increase of the mean heart rate of 3.7% occurred following cyclopentolate 0.5% (1 d) and tropicamide 0.5% (2 d) administration,[@R7] additionally, an increase in heart rate of 10%±10.6% occurred following phenylephrine 2.5%, tropicamide 0.5% and cyclopentolate 0.5% (2 d) administration.[@R19]

There were no significant cardiovascular changes recorded in the microdrop groups, which is likely explained by the lower total dose leading to minimal systemic absorption.[@R17]

Blood pressure and heart rate results from Caputo (1982),[@R9] Chew (2005),[@R20] Luo (2014),[@R21] Mirmanesh (1992),[@R22] Pharmonvaechavan (2012),[@R23] Rosales (1981),[@R24] Rush (2004)[@R25] were not able to be included in the analysis because SD or SE and p values were not included in the publication. Blood pressure results from Rosales (1981)[@R24] were not able to be included in the analysis because SD and p values were not included in the publication. Ogut (1996)[@R26] results were not able to be included because p values were not presented. Luo (2014)[@R21] commented that no infants had bradycardia, and Lux's (2016)[@R27] study design intended to collect data on pulse rate and blood pressure but did not provide results for this.

Very specific cardiovascular monitoring occurred in a study of 42 premature infants, where mean anterior and middle cerebral artery blood flow, heart rate, end diastolic velocity (anterior and middle cerebral artery) and blood pressure was measured. Results from this observational study found no statistically significant results; however, this study may have been underpowered to detect a statistically significant result.[@R6]

Fourteen cardiovascular adverse events were documented in case reports ([table 5](#T5){ref-type="table"}). All infants had phenylephrine administered; however, due to the variation in regimens, no themes of likely causative regimens were determined. Tachycardia and bradycardia were the most common reports, and cardiopulmonary arrest and pulseless being the most clinically significant.

###### 

Summary of cardiovascular events

  Paper                   Regimen                                  Tachycardia   Bradycardia   Other
  ----------------------- ---------------------------------------- ------------- ------------- -----------------------------------
  Ahmad (2016)[@R47]      P 1%, C 0.2%, (unknown d)                2             2             Premature atrial contractions (2)
  Ozgun (2014)[@R29]      P 1.25%, C 0.5% (2 d)                    1                            
  Socarras (2017)[@R48]   P 2.5%, T(unknown concentration) (2 d)   1                           Arterial hypertension (1)
  Ahmad (2016)[@R47]      P 1%, C0.2% (3 d)                                                    Cardiopulmonary arrest (1)
  Wood (2009)[@R49]       P 1%, C 0.2% (1--2 d)                                  2             Pulseless (1)
  Siu (2011)[@R30]        P 2.5%, C 1% (2 d)                                     1              

C, cyclopentolate;P, phenylephrine;T, tropicamide;d, standard drop.

Gastrointestinal {#s3-4}
----------------

### Key findings {#s3-4-1}

1.  Phenylephrine can cause vasoconstriction of the blood supply to the gut, and anticholinergic effect on the gut reduces peristalsis; hence, both mechanisms of actions affect the gastrointestinal system.

2.  Feed intolerance, abdominal distention, ileus and NEC are gastrointestinal adverse effects associated with mydriatic use.

3.  All cases of gastrointestinal adverse effects had phenylephrine administered, and the majority had cyclopentolate. Only one case involved the use of tropicamide.

4.  Three infants have died with complications associated with NEC, possibly linked with mydriatic use.

5.  All safety and case reports had regimens where standard drops were used.

Reduced gastric volume, increased abdominal girth, increased feed intolerance and increased incidence of NEC were some of the gastrointestinal adverse effects investigated by authors ([table 6](#T6){ref-type="table"}). Additionally, Jiang (2016)[@R10] found that approximately 10% of infants developed NEC following phenylephrine 0.5% and tropicamide 0.5% (3 d) administration (p\<0.01), and new cases of upper digestive tract haemorrhage also increased (n=139, p\<0.00).[@R10]

###### 

Publications providing data on gastric volume, abdominal girth and feed intolerance

  Paper                   Regimen              Mean gastric volume±SD (μmol/kg/hour)                     Abdominal girth 24 hours post (cm)   Feed intolerance
  ----------------------- -------------------- --------------------------------------------------------- ------------------------------------ ------------------
  Chew (2005)[@R20]       P 2.5%, C 1% (3 d)   --                                                        25.2±1.6                             50%
  P 2.5%, T 1% (3 d)      --                   27.1±2.0                                                  25%                                  
  P 1%, C 0.2% (3 d)      --                   27.1±2.9                                                  25%                                  
  Isenberg (1985)[@R15]   C 0.25% (2 d)        10±7                                                      --                                   --
  C 0.5% (2 d)            Approx. 2.5±1*\**    --                                                        --                                   
  Mitchell (2016)[@R28]   P 1%, C 0.2% (3 d)   Increased gastric residual (statistically significant)†   --                                   --

\*P\<0.01.

†Data not presented.

C, cyclopentolate;P, phenylephrine;T, tropicamide;d, standard drop.

Antral and duodenal motor activity and gastric emptying, pre and post phenylephrine 2.5% and cyclopentolate 0.5% (2 d) administration was measured in 11 premature infants.[@R8] Duodenal motor contractions decreased nearly fourfold after mydriatic instillation and gastric emptying was significantly delayed ([table 5](#T5){ref-type="table"}).[@R8]

Results from an intervention study (n=10), demonstrated a reduction in gastric acid secretion of approximately 58% following cyclopentolate 0.5% administration (p\<0.01) ([table 6](#T6){ref-type="table"}).[@R15] This is compared with a RCT (n=25), where gastric residuals increased following phenylephrine 1% and cyclopentolate 0.2% (3 d) administration (p=0.01) ([table 6](#T6){ref-type="table"}).[@R28]

No statistically significant results from a RCT (n=39) for abdominal girth or feed intolerance occurred following the administration of phenylephrine 2.5% and cyclopentolate 1% (3 d) or phenylephrine 2.5% and tropicamide 1% (3 d) or phenylephrine 1% and cyclopentolate 0.2% (3 d).[@R20]

Abdominal distention (n=7), NEC (n=4), transient ileus (n=3) and feed intolerance (n=3) are the most common adverse effects documented in case reports ([table 7](#T7){ref-type="table"}). Three infants died following complications associated with NEC.[@R29]

###### 

Summary of significant gastrointestinal events

  --------------------------------------------------------------------------------------------------------------
  Paper                         Regimen                     NEC and death   NEC   Other
  ----------------------------- --------------------------- --------------- ----- ------------------------------
  CARM (2014)[@R31]             P 2.5%, C 0.5% (3 d)        1                     

  Ozgun (2014)[@R29]            P 1.25%, C 0.5% (2 d)       1                     Abdominal distention (1)

  Siu (2011)[@R30]              P 2.5%, C 1% (2 d)          1               1     Abdominal distension (1)\
                                                                                  Milk intolerance (1)\
                                                                                  Pneumatosis intestinalis (1)

  CARM (2002)[@R35]             P 1%, C 0.5% (1 d)                                Abdominal distention (1)

  Degrimencioglu (2014)[@R50]   P 2.5%, T 0.5% (3 d)                              Feed intolerance (1)\
                                                                                  Abdominal distension (1)\
                                                                                  Transient ileus (1)

  Socarras (2017)[@R48]         P 2.5%, T(unknown%) (2 d)                         Feed intolerance (1)\
                                                                                  Abdominal distension (1)

  Sarici (2001)[@R51]           P 2.5%, C 0.5% (2 d)                              Vomiting (1)\
                                                                                  Abdominal distention (1)\
                                                                                  Gastric dilation (1)

  Lim (2003)[@R52]              P 1%, C 0.2% (3 d)                                Abdominal distention (1)\
                                                                                  Transient ileus (1)

  Lim (2003)[@R52]              P 1%, C 0.2% (3 d)                                Transient ileus (1)
  --------------------------------------------------------------------------------------------------------------

C, cyclopentolate;CARM, Centre for Adverse Reactions Monitoring; NEC, necrotising enterocolitis;P, phenylephrine;T, tropicamide;d, standard drop.

Respiratory {#s3-5}
-----------

### Key findings {#s3-5-1}

1.  Unwanted respiratory effects could occur via alpha-agonist mediated activity. Phenylephrine has a stimulatory effect on increasing airway smooth muscle tension, which leads to bronchoconstriction, reduced oxygen saturations and apnoea.

2.  Infants with bronchopulmonary dysplasia (BPD) are more likely to experience respiratory adverse effects compared with those without BPD.

3.  Infants on oxygen support are more likely to have higher serum concentrations of cyclopentolate than those not on oxygen support.

4.  The most common adverse effects identified in case reports are apnoea and desaturation.

5.  All safety and case reports had regimens where standard drops were used.

Oxygen saturation and apnoea effects were investigated in just a few studies ([table 8](#T8){ref-type="table"}). Results from a pilot observational study (n=42) demonstrated no change in oxygen saturations following the use of phenylephrine 2.5% and tropicamide 0.5% (3 d) (p\>0.05) ([table 8](#T8){ref-type="table"}).[@R6] This compares audit data from 1183 infants, where significant increases in apnoea were seen following significantly lower doses of phenylephrine 0.5% and equal dose of tropicamide 0.5% (3 d) (p\<0.05) ([table 6](#T6){ref-type="table"}).[@R10]

###### 

Publications providing data on respiratory adverse effects

  Paper                          Regimen                Adverse effect
  ------------------------------ ---------------------- ------------------------------------------------------------------------------------------------------------------------------------------------
  Alshafei (2017)[@R6]           P 2.5%, T 0.5% (3 d)   No adverse effect on oxygen saturation, not statistically significant
  Jiang (2016)[@R10]             P 0.5%, T 0.5% (3 d)   Apnoea: statistically significant increase (p\<0.05).
  Mitchell (2016)[@R28]          P 1%, C 0.2% (3 d)     Desaturations more likely in oxygen therapy group (p=0.01)
  Mirmanesh (1992)[@R22]         P 2.5% (3 d)           Infants with BPD;Reduction in mean pulmonary compliance (p\<0.03)Increased mean total resistance (p\<0.01)Reduced expiratory airflow (p\<0.03)
  Punyawattanporn (2009)[@R41]   Not identified         Apnoea: one infant.

C, cyclopentolate;P, phenylephrine;T, tropicamide; d, standard drop.

Following phenylephrine 2.5% (3 d) administration, infants with BPD are more likely to experience a reduction in mean pulmonary compliance (p\<0.03), increased mean total resistance (p\<0.01) and reduced expiratory airflow (p\<0.03), compared with infants without BPD.[@R22]

Cyclopentolate serum concentrations were measured following cyclopentolate 0.2% (3 d) administration.[@R28] Results show that infants who were receiving oxygen therapy, had significantly higher cyclopentolate concentrations, than infants who were not receiving oxygen therapy (p=0.01). The infants with higher cyclopentolate concentrations and who were receiving oxygen therapy also were more likely to have desaturations (p=0.01).[@R28]

Lux's (2016)[@R27] study design intended to collect data on oxygen saturation and respiratory frequency but did not provide results for this.[@R27]

Thirteen respiratory associated events are documented with the most common are apnoea (n=5), desaturations (n=3) and other respiratory events (n=5) ([table 9](#T9){ref-type="table"}).

###### 

Summary of respiratory events

  -----------------------------------------------------------------------------------------------------
  Paper                         Regimen                 Apnoea   Desaturation   Other
  ----------------------------- ----------------------- -------- -------------- -----------------------
  Sarici (2001)[@R51]           P 2.5%, C 0.5% (2 d)    1                       

  Degirmencioglu (2014)[@R50]   P 2.5%, T 0.5% (3 d)    1                       

  Wood (2009)[@R49]             P 1%, C 0.2% (1--2 d)   1                       Shallow breathing (1)

  Wood (2009)[@R49]             P 1%, C 0.2% (1--2 d)   1                       

  CARM (2002)[@R35]             P 1%, C 0.5% (1 d)      1        1              

  Siu (2011)[@R30]              P 2.5%, C 1% (2 d)               1              

  Kim (2015)[@R53]              P 2.5%, T 0.5% (2 d)             1              Mild wheezing (1)

  Kim (2015)[@R53]              P 2.5%, T 0.5% (2 d)                            Bronchospasm (1)\
                                                                                Mild wheezing (1)

  Ozgun (2014)[@R29]            P 1.25%, C 0.5% (2 d)                           Tachyapnoea (1)
  -----------------------------------------------------------------------------------------------------

C, cyclopentolate;P, phenylephrine;T, tropicamide;d, standard drops.

Central nervous system {#s3-6}
----------------------

No safety data on CNS adverse effects has been published. The only CNS data available are case reports and involve seizures (n=5) and anticholinergic syndrome (n=1).[@R31] All cases involved the use of cyclopentolate 0.5%. The mechanism for seizure activity following alpha agonist and anticholinergic agents is unknown.

Dermal {#s3-7}
------

Three infants experienced periorbital pallor following phenylephrine 2.5% and tropicamide 0.5% (1 d).[@R12] Conversely, skin flushing was observed following cyclopentolate 1% (2 d) and phenylephrine 10% (2 d) administration.[@R17]

A mechanism for skin flushing is unknown, and skin flushing seems very unusual considering the mechanism of action of phenylephrine. If phenylephrine eye drop excess is not wiped away from the eye area, this allows for phenylephrine to be absorbed dermally. Subsequent vasoconstriction occurs which results in periorbital pallor.

Ten dermal events have been reported, and these include eyelid swelling (n=4) and periorbital pallor (n=6).[@R35]

Other {#s3-8}
-----

There were a few other case reports identified which did not fit into the above themes, and the cases involved cutis marmorata, leukopaenia, neutropaenia and renal failure.[@R29]

Discussion {#s4}
==========

This review has identified that low dose mydriatics have comparable efficacy to larger doses; therefore, irrespective of mydriatic regimen, sufficient pupil dilation occurs at low doses.

Of all the regimens reviewed for efficacy, phenylephrine 1% and cyclopentolate 0.2% (1--2 d) is the lowest combination dose that provides sufficient pupil dilation.[@R40] However, phenylephrine 2.5% and cyclopentolate 0.5% (2--3 d) is the recommended regimen in the UK guideline,[@R3] although there is no known publication evaluating the efficacy of the three-drop regimen. This dose seems unnecessarily high considering the current body of knowledge about efficacy. Regarding safety, results from a retrospective audit of 138 premature infants who underwent ROPEE's using the UK guideline regimen, highlighted six cases of harm ranging from apnoea, desaturations and NEC,[@R43] there is an unpublished case of death associated with NEC[@R31] and one reported case of a seizure.[@R33]

Although the extent of mydriatic harm has not been fully investigated, a few studies signal the potential for cardiovascular, gastrointestinal and respiratory adverse effects. It is very likely that our most vulnerable premature infants with pre-existing medical conditions are the ones who are more likely to experience adverse effects associated with mydriatics and are less likely to be able to compensate for any medicine related harms. Medical practice is evolving in both the developed and low and middle-income countries, and as the ROPEE standard of care is being extended, it is likely that there will be an increase in adverse effects post-ROPEE in centres who are using high-dose mydriatic regimens.

Simple concepts that need further investigations are giving low concentrations as a single microdrop. This method would reduce mydriatic exposure to the systemic circulation.[@R1]

Infants with dark irides may also need special dosing consideration, as it is hypothesised that higher doses may need to be administered in people with dark pigmented iris.[@R16] This implication for dosing requirements could also have potential increased risks associated with side effects and subsequent harm. Currently, international guidelines do not offer dose adjustment recommendations based on iris colour. Further research is required to ascertain this potential association.

And lastly, readily available commercial products are prepared at higher concentrations than what is needed, and current packaging is suitable for adult dose administration and not neonatal dosing. Further research on appropriate formulations and packaging for commercial products needs to occur.

Limitations {#s4-1}
-----------

Limitations of this systematic review are (1) the non-randomised trials included in the review were not designed as comparative studies, (2) case reports were assessed as reported and no independent assessment was carried out for causality, (3) there was a significant amount of unclear bias in the publications and (4) papers not available in English were not included in this review.

An assumption was made that if microdrop administration was not specified and that standard drops were administered.

Confounders, such as pre-existing medical conditions and pain associated with ROPEE, were often not mentioned in the publications included in the analysis.

Number of case reports are likely to be much higher. It is estimated that approximately 10% of adverse drug reactions are ever reported, and very few of these make it to publication.

Conclusions {#s5}
===========

Current international dosing guidance seems unnecessarily high, especially when the reviewed literature suggest that lower doses are effective. All studies investigating efficacy were underpowered due to limited sample size; however, the lowest effective regimen appears to be phenylephrine 1% and cyclopentolate 0.2% (1 d).[@R42] Microdrop administration of this and other regimens would further increase the safety profile. However further investigation and validation needs to occur.

In conclusion, low doses of mydriatics appear to be effective and are likely to be associated with a safer adverse effect profile.
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